Advice
in the absence of a submission from the holder of the marketing authorisation:
letermovir (Prevymis®) is not recommended for use within NHSScotland.
Indication under review: for prophylaxis of cytomegalovirus (CMV) disease in CMV-seronegative adults who have received a kidney transplant from a CMV-seropositive donor [D+/R-].
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result, we cannot recommend its use within NHSScotland.
Download detailed advice215KB (PDF)
Medicine details
- Medicine name:
- letermovir (Prevymis)
- SMC ID:
- SMC2853
- Indication:
For prophylaxis of cytomegalovirus (CMV) disease in CMV-seronegative adults who have received a kidney transplant from a CMV-seropositive donor [D+/R-].
- Pharmaceutical company
- Merck Sharp & Dohme Ltd
- BNF chapter
- Infections
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 11 August 2025